Premium
Expression of β‐catenin and p53 are prognostic factors in deep aggressive fibromatosis
Author(s) -
Gebert C,
Hardes J,
Kersting C,
August C,
Supper H,
Winkelmann W,
Buerger H,
Gosheger G
Publication year - 2007
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/j.1365-2559.2007.02619.x
Subject(s) - immunohistochemistry , tissue microarray , aggressive fibromatosis , fibromatosis , catenin , cd34 , desmin , epidermal growth factor receptor , cancer research , biology , medicine , pathology , oncology , wnt signaling pathway , receptor , stem cell , gene , vimentin , biochemistry , genetics
Aims: To determine the prognostic significance of β‐catenin in aggressive fibromatosis and to identify potential molecular markers for new targeted therapies. Methods and results: A tissue microarray of 37 cases of deep aggressive fibromatosis was constructed and subjected to immunohistochemical analysis for β‐catenin, p53, smooth muscle actin (SMA), desmin, Ki67, c‐erbB2, epidermal growth factor receptor (EGFR), c‐kit, CD34 and S100. Complete clinical follow‐up was available for 23 patients. Nuclear β‐catenin expression was associated with an increased rate of local tumour recurrence (60.0% 1‐year and 0% 5‐year event‐free survival; P < 0.05). Furthermore, p53 expression was associated with an increased risk of tumour recurrence (50% 1‐year event‐free survival rate and 0% 5‐years event‐free survival rate, P < 0.05). The coexpression of p53 and β‐catenin was significantly correlated ( P < 0.05). No statistically significant association was seen between MIB1 and p53 or β‐catenin expression, respectively. No expression of EGFR, c‐erbB2 or c‐kit was seen. Conclusions: The overexpression of β‐catenin and p53 is associated with a decreased event‐free survival in deep aggressive fibromatosis. Further studies are required to establish whether these findings can lead to an improvement in the treatment of this rare neoplasm.